Cargando…

The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients

Endometrial cancer is one of the most common cancers of the reproductive organ in women. The incidence of it increases from year to year. In our study we assessed role of FGF21 and FGF23 in the diagnostics of patients with endometrial cancer. The study involved 182 patients, who were undergoing abra...

Descripción completa

Detalles Bibliográficos
Autores principales: Cymbaluk-Płoska, Aneta, Gargulińska, Paula, Chudecka-Głaz, Anita, Kwiatkowski, Sebastian, Pius-Sadowska, Ewa, Machaliński, Bogusław
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344631/
https://www.ncbi.nlm.nih.gov/pubmed/32570721
http://dx.doi.org/10.3390/diagnostics10060414
_version_ 1783555989183660032
author Cymbaluk-Płoska, Aneta
Gargulińska, Paula
Chudecka-Głaz, Anita
Kwiatkowski, Sebastian
Pius-Sadowska, Ewa
Machaliński, Bogusław
author_facet Cymbaluk-Płoska, Aneta
Gargulińska, Paula
Chudecka-Głaz, Anita
Kwiatkowski, Sebastian
Pius-Sadowska, Ewa
Machaliński, Bogusław
author_sort Cymbaluk-Płoska, Aneta
collection PubMed
description Endometrial cancer is one of the most common cancers of the reproductive organ in women. The incidence of it increases from year to year. In our study we assessed role of FGF21 and FGF23 in the diagnostics of patients with endometrial cancer. The study involved 182 patients, who were undergoing abrasion due to perimenopausal bleeding. FGF21, FGF23, and leptin concentration were quantified in serum by multiplex fluorescent bead-based immunoassays (Luminex Corporation). The median of FGF21 protein (181.8 pg/mL) as well as leptin (16.9 ng/mL) in patients with endometrial cancer was statistically significant higher compared to median of those proteins among patients from control group (152.1 pg/mL and 14.1 ng/mL, respectively). However, no significant differences were found in these groups at median FGF23 concentrations. For FGF21 and leptin, the AUC values were 0.81/0.79, while FGF23, the AUC values was 0.66 for all study patients. Leptin and FGF21 concentrations were statistically significantly higher in patients with poorly differentiated G3 tumors compared to patients with moderately differentiated G2 tumors and with moderately differentiated G2 with highly differentiated G1 respectively: p = 0.02/p = 0.03 and p = 0.02/p = 0.005. FGF21 appears to be useful as a diagnostic as well as prognostic factor in patients with endometrioid endometrial carcinoma.
format Online
Article
Text
id pubmed-7344631
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73446312020-07-09 The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients Cymbaluk-Płoska, Aneta Gargulińska, Paula Chudecka-Głaz, Anita Kwiatkowski, Sebastian Pius-Sadowska, Ewa Machaliński, Bogusław Diagnostics (Basel) Article Endometrial cancer is one of the most common cancers of the reproductive organ in women. The incidence of it increases from year to year. In our study we assessed role of FGF21 and FGF23 in the diagnostics of patients with endometrial cancer. The study involved 182 patients, who were undergoing abrasion due to perimenopausal bleeding. FGF21, FGF23, and leptin concentration were quantified in serum by multiplex fluorescent bead-based immunoassays (Luminex Corporation). The median of FGF21 protein (181.8 pg/mL) as well as leptin (16.9 ng/mL) in patients with endometrial cancer was statistically significant higher compared to median of those proteins among patients from control group (152.1 pg/mL and 14.1 ng/mL, respectively). However, no significant differences were found in these groups at median FGF23 concentrations. For FGF21 and leptin, the AUC values were 0.81/0.79, while FGF23, the AUC values was 0.66 for all study patients. Leptin and FGF21 concentrations were statistically significantly higher in patients with poorly differentiated G3 tumors compared to patients with moderately differentiated G2 tumors and with moderately differentiated G2 with highly differentiated G1 respectively: p = 0.02/p = 0.03 and p = 0.02/p = 0.005. FGF21 appears to be useful as a diagnostic as well as prognostic factor in patients with endometrioid endometrial carcinoma. MDPI 2020-06-18 /pmc/articles/PMC7344631/ /pubmed/32570721 http://dx.doi.org/10.3390/diagnostics10060414 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Cymbaluk-Płoska, Aneta
Gargulińska, Paula
Chudecka-Głaz, Anita
Kwiatkowski, Sebastian
Pius-Sadowska, Ewa
Machaliński, Bogusław
The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients
title The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients
title_full The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients
title_fullStr The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients
title_full_unstemmed The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients
title_short The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients
title_sort suitability of fgf21 and fgf23 as new biomarkers in endometrial cancer patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344631/
https://www.ncbi.nlm.nih.gov/pubmed/32570721
http://dx.doi.org/10.3390/diagnostics10060414
work_keys_str_mv AT cymbalukpłoskaaneta thesuitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients
AT gargulinskapaula thesuitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients
AT chudeckagłazanita thesuitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients
AT kwiatkowskisebastian thesuitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients
AT piussadowskaewa thesuitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients
AT machalinskibogusław thesuitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients
AT cymbalukpłoskaaneta suitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients
AT gargulinskapaula suitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients
AT chudeckagłazanita suitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients
AT kwiatkowskisebastian suitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients
AT piussadowskaewa suitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients
AT machalinskibogusław suitabilityoffgf21andfgf23asnewbiomarkersinendometrialcancerpatients